Silverarc Capital Management
CAMP icon

Silverarc Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

Silverarc Capital Management’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$740K Sell
183,063
-470,531
-72% -$1.93M 0.09% 66
2026
Q2 		$2.86M Hold
653,594
– – 0.3% 59
2026
Q1 		$2.88M Buy
+653,594
New +$3.1M 0.29% 53
2025
Q4 		– Sell
-653,594
Closed -$1.96M – 74
2025
Q3 		$1.96M Buy
+653,594
New +$1.21M 0.26% 62

Other funds holding CAMP

Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Stonepine Capital Management
Stonepine Capital Management Bend, Oregon $159M AUM 62.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Silverarc Capital Management's CAMP Position: Q3 2026 in Review

Silverarc Capital Management reduced its CAMP4 Therapeutics (CAMP) stake by 72% in Q3 2026, selling an estimated $1.93M and leaving 183,063 shares worth $740K. The position accounts for 0.09% of the portfolio, ranked #66.

Silverarc Capital Management first reported a position in CAMP in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.88M in Q1 2026. 39 funds tracked by Wall St. Rank hold CAMP as of Q3 2026.

  • Silverarc Capital Management held 183,063 shares of CAMP4 Therapeutics worth $740K as of Q3 2026.
  • Silverarc Capital Management sold 470,531 CAMP4 Therapeutics shares in Q3 2026, an estimated $1.93M.
  • CAMP4 Therapeutics made up 0.09% of Silverarc Capital Management's portfolio in Q3 2026, its #66 holding.
  • Silverarc Capital Management first reported a position in CAMP4 Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Silverarc Capital Management's CAMP4 Therapeutics position peaked at $2.88M in Q1 2026.
  • 39 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q3 2026.

Based on Silverarc Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.